Good Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection
|
|
- Lindsay Gilbert
- 5 years ago
- Views:
Transcription
1 BRIEF REPORT: CLINICAL SCIENCE Good Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection Gustavo D. Lopardo, MD,* Emiliano Bissio, MD,* María del C. Iannella,* Alejandro D. Crespo, MD,* Daniela B. Garone, MD, and Lidia I. Cassetti, MD* Objective: To evaluate neurocognitive performance in patients with preserved immunological status using the International HIV Dementia Scale (IHDS) and compare patients on and off highly active antiretroviral therapy (HAART). Design: Cross-sectional study. Methods: Outpatients with more than 350 CD4 cells per cubic millimeter underwent evaluation by means of the IHDS, a cross-cultural scale designed to identify HIV-positive patients at risk for dementia. Results: A total of 260 patients were included, 158 on HAART and viral load,1000 copies per ml and 102 on treatment naïve. Mean age was 38.2 (SD 8.03) years, 86% were male. Mean score was 10.9 (SD 1.77). Only age correlated with a significantly different score; younger patients performed better. When patients on and off HAART were compared, we found no significant differences in age, sex, time from diagnosis, educational level, risk factor for HIV acquisition, and current CD4 count. CD4 nadir was lower for patients on HAART: (200.95) vs (233.33), P, There was no difference between the scores obtained by patients on and off HAART (mean 11.0, SD 2.08; mean 10.8, SD 1.17; respectively, P = 0.70). There was no difference according to efavirenz use. Conclusions: Patients with preserved immunity performed well on IHDS. It didn t seem to be any difference between patients on and off HAART regarding neurocognitive status. Key Words: HIV infection, HIV dementia, international HIV dementia scale, neurocognitive disorders (J Acquir Immune Defic Syndr 2009;52: ) INTRODUCTION Cognitive and motor impairment is still recognized as a common complication in HIV-1 infection, presenting as a wide spectrum of disorders ranging from HIV-associated Received for publication December 8, 2008; accepted April 30, From the *Fundación del Centro de Estudios Infectológicos, FUNCEI, Buenos Aires, Argentina; Department of Infectious Diseases, Hospital Profesor Bernardo Houssay, Vicente López, Argentina; and Helios Salud, Buenos Aires, Argentina. Conflicts of interest: none. Correspondence to: Gustavo D. Lopardo, MD, Fundación del Centro de Estudios Infectológicos, FUNCEI. French 3085 (C1425AWK), Buenos Aires, Argentina ( glopardo@intramed.net.ar). Copyright Ó 2009 by Lippincott Williams & Wilkins asymptomatic neurocognitive impairment (ANI) to severe forms of cognitive impairment, known as HIV-1 associated dementia (HAD). In early HIV-1 infection, prevalence of ANI is about 20%. 1 In patients with AIDS, prevalence of any cognitive impairment is 52% in those younger than 50 and more than 80% in those older than 50. 2,3 The role of HIV-1 proliferation on the development of HIV dementia is controversial. Although viral strains replicating in brain macrophages may play a role in the pathogenesis of brain injury, a heavy viral burden in brain has not been linked consistently with clinical HIV dementia. 2,3 Neurocognitive impairment should be diagnosed and assessed early in the course of HIV-1 infection because it is associated with increased mortality, 4,5 may interfere with adherence, 6 and may be treated with antiretroviral agents. Giancola et al 7 demonstrated that control of plasma levels of HIV-1 RNA in less advanced HIV patients affected by mild neurocognitive disorders could be sufficient to improve the deficits. As HIV is now a chronic and manageable disease, the relative importance of neurological morbidity has increased. Neuropsychological testing is a critical component of the diagnosis, but it is time consuming, language and educational dependent, and often not available in developing countries. Mini Mental State Exam by Folstein et al 8 was designed to screen for cortical dementia, it is therefore not sensitive for detecting subcortical dementia such as HIV dementia. 9 The HIV Dementia Scale was designed as a brief but sensitive screening instrument to identify HIV-1 infected patients at risk for dementia. However, it is difficult for nonneurologists to administer and includes subtests which may be difficult for individuals with a nonwestern educational background. Sacktor et al 10,11 developed a practical cross-cultural screening instrument, the International HIV Dementia Scale (IHDS). It offers several advantages: it is easy to perform, requires only 2 3 minutes by nonneurologists in an outpatient setting, requires no special instrumentation, and detects subcortical damage such as HIV dementia. It does not require knowledge of the English language. The sensitivity and specificity of the IHDS are comparable to the sensitivity (71%) and specificity (46%) of the Grooved Pegboard nondominant hand test, an established test for HIV dementia The IHDS identifies individuals at risk for HIV dementia within the International community, particularly in developing countries. However, it should not be used as a replacement for a full neuropsychological testing to confirm a diagnosis of HIV dementia J Acquir Immune Defic Syndr Volume 52, Number 4, December 1, 2009
2 J Acquir Immune Defic Syndr Volume 52, Number 4, December 1, 2009 Neurocognitive Performance in HIV Infection According to the Department of Health and Human Services (DHHS) guidelines, most asymptomatic HIV-1 infected patients with CD4 cell count.350 cells per cubic millimeter would not require antiretroviral therapy. 15 Nevertheless, there is concern that patients who do not receive antiretroviral therapy may develop neurocognitive impairment despite preserved immunological status. The impact of continuing viral replication in this population is not known. The mean CD4 cell count for new cases of HIV dementia is increasing. 16 Sacktor et al 17 assessed the temporal trends in the incidence rates of HIV dementia from 1990 to 1998 in the Multicenter AIDS Cohort Study. They found that the incidence decreased dramatically since the introduction of highly active antiretroviral therapy (HAART) in 1996 compared with the incidence rates from 1990 to However, they also found that the proportion of new cases of HIV-1 associated dementia with higher CD4 count increased compared with the early 1990s. Our hypothesis was that asymptomatic HIV-infected patients with high CD4 cell count could be at risk of developing neurocognitive impairment, particularly for those who do not receive HAART. The objective of this study was to evaluate the presence of neurocognitive impairment in patients with preserved immunological status using the new IHDS in a developing country and to compare patients with controlled plasma viral load replication on HAART with those not receiving HAART. METHODS This was a cross-sectional study. The population consisted of outpatients with CD4 cell count higher than 350 cells per cubic millimeter from 2 HIV clinics and 1 hospital in Buenos Aires. The Ethics committee of the participating institutions approved the study, and participants signed informed consent to participate. Patients were eligible if they had confirmed HIV-1 infection, were older than 18 years, had a CD4 cell count above 350 cells per cubic millimeter, and HIV-1 viral load measured in the previous 3 months. Patients with a history of psychiatric disease, including depression, current use of recreational drugs, and current or previous opportunistic infections, and patients on HAART with viral load.3 log were excluded. All patients accomplishing inclusion criteria, who assisted to an outpatient visit, were offered to participate in the study. Patients were divided in 2 groups: those on HAART and VL,1000 and those treatment-naïve. All the patients underwent evaluation by means of IHDS, which consist of 3 subsets 9 : timed fingertapping, timed alternating hand sequence test, and recall of 4 words at 2 minutes (score #10 suggestive of dementia). Four different physicians, all specialists in infectious diseases, performed the test. The following variables were assessed: age, gender, educational level, risk factor for acquisition of HIV infection, time from diagnosis of HIV infection, current CD4 cell count, CD4 cell count nadir, and current viral load. Participants on HAART were stratified according to the use of efavirenz. We analyzed the scores according to different variables and then compared those patients on HAART with controlled plasma viral load replication with those not receiving HAART. Demographic variables, age, gender, educational level, risk factor for acquisition of HIV infection, time from diagnosis of HIV infection, current CD4 cell count, CD4 cell count nadir, and current viral load were analyzed between groups to ascertain homogeneity before performing statistical analysis of scores. For categorical variables, such as gender, educational level, risk for acquisition of HIV infection, time from diagnosis of HIV infection (,5 years, $5 years) x 2 or Fisher exact tests were used. Mean age, mean current CD4 cell count, and mean CD4 cell count nadir and mean maximal viral load were compared with Student t test for independent samples. Wilcoxon test was applied to analyze current viral load. Demographic variables were stratified; mean score and number of subjects per strata were computed and analyzed. x 2 or Fisher exact tests were applied. Univariate and multivariate analyses were performed. All the variables were tested for univariate analysis. Logistic regression was applied to identify risk factors associated to HIV dementia among the analyzed variables. IHDS score was considered the dependent variable. Educational level was excluded because of the homogeneity of the sample; also intravenous drug users as a risk factor for HIV acquisition was excluded due to the low number of patients in this group. All tests were 2 tailed; P, 0.05 was considered statistically significant. Software SPSS 15.0, Chicago, IL, 2007 was used. RESULTS During a 2-month period, 260 subjects were enrolled, 158 on HAART, and 102 treatment naive. Mean age was 38.2 years, (SD 8.03, r = 21 73), 86% were men, 96% acquired HIV sexually (64% men who have sex with men, 32% heterosexual) (Table 1). Mean score was 10.9 (SD 1.77). Of all the variables analyzed, only age was found to be associated with a different performance. The score was significantly higher in the group of patients years old compared with those years old. Mean scores were 11.1 and 10.2, respectively; P, 0.001, Fisher (Table 2). None of the other variables showed a statistically significant difference. Regarding educational level, most patients were highly educated, so it was not possible to perform the analysis. More than 90% of participants had finished high school or had a university degree. Eighty-three patients were on efavirenz, they did not perform different from the rest of the population (Table 1). Age, gender, risk factor for HIV acquisition, time from diagnosis of HIV infection, educational level, and current CD4 cell count were similar between groups. CD4 cell count nadir was lower for patients on HAART: (200.95) and (233.33) for patients off HAART, P, (t test). Median current viral load was,50 copies per milliliter (interquartile range:,50 to,50) and 21,102 copies per milliliter (interquartile range: ,900), respectively. When we compared both groups, those on therapy with those off, we found no difference between the distribution of q 2009 Lippincott Williams & Wilkins 523
3 Lopardo et al J Acquir Immune Defic Syndr Volume 52, Number 4, December 1, 2009 TABLE 1. Variables Analyzed in Patients on and Off HAART Total (N = 260) On HAART (n = 158) Off HAART (n = 102) P Male sex (n = 259), n (%) 222/259 (86) 131/158 (83) 91/102 (89) 0.21 (Fisher) Mean age (n = 259) 38.2 (8.03) 38.9 (7.78) (n = 157) 37.1 (8.31) (n = 102) 0.07 (t test) Risk factor for HIV acquisition IVDU, n (%) 9/241 (4) 6/141 (4) 3/100 (3) 0.09 (x 2, Pearson) Heterosexual, n (%) 78/241 (32) 53/141 (38) 25/100 (25) MSM, n (%) 154/241 (64) 82/141 (58) 72/100 (72) Current CD4 (n = 260) (239.76) (239.98) (n = 158) (239.43) (n = 102) 0.32 (t test) Current viral load (n = 255), median (interquartile range) 50 (50 10,850) 50 (50 50) (n = 157) 21,102 ( ,900) (n = 98),0.001 (Wilcoxon, w = 12,686) CD4 cell count nadir (n = 250) (246.13) (200.95) (n = 149) (233.33) (n = 101),0.001 (t test) Efavirenz use (n = 155), n (%) 83/155 (54) Educational level (n = 225) 209/225 (93) 118/128 (92) 91/97 (94) 0.80 (Fisher) (finished high school), n (%) Maximal viral load, mean (SD) (n = 233) 288,995.2 (843,002.00) 270,953.7 (319,552.31) (n = 136) 314,290.6 (1,254,076.90) (n = 97),0.001 (t test) MSM, men who have sex with men. scores: mean, 11.0 (2.08) and mean, (1.17), respectively, P = 0.70 (Fisher). Finally, the score was classified as #10 points or.10 points. A logistic regression model analysis was performed to assess if any of the variables analyzed was an independent risk factor for a lower score. The score was considered the dependent variable. According to the logistic regression model, only age was related to the score. Advanced age was a significant risk factor for IHDS score #10 (odds ratio = 3.5, 95% confidence interval: 1.36 to 8.99; P, 0.01). Younger participants, those aged 21 44, performed better (Fig. 1). DISCUSSION The results of our study do not confirm our hypothesis. According to the IHDS, our population do not have a significant risk of HIV-associated dementia. Besides, the presence of controlled plasma viral load replication does not seem to show any benefit on the risk of developing HIV dementia in this population. In univariate and multivariate analysis, only older patients were at higher risk. Neither gender, risk factor, time from diagnosis of HIV-1 infection, current CD4 cell count and viral load, nor CD4 cell count nadir were associated with risk. It is well known that efavirenz may cause neurological side effects and could interfere in neurocognitive performance. 18 We did not find any difference in patients receiving efavirenz and those not. Epidemiological research initiatives identified an increased rate of HIV-associated dementia among older patients. 19 It is not clear if there is an additive or synergistic relationship between aging and HIV on neuropsychological TABLE 2. Neurological Performance According to Different Variables Variable Strata n Mean Score P Age (n = 259) (1.85),0.001 (Fisher) (1.17) Sex (n = 259) Men (1.86) 0.45 (Fisher) Women (1.06) Risk factor for acquisition of HIV-1 infection (n = 241) Heterosexual (1.16) (x 2, Pearson) MSM (1.06) IVDU (0.85) Time from diagnosis of HIV-1 infection (n = 251),5 yrs (1.14) 0.48 (Fisher) $5 yrs (2.05) Current CD4 cell count (n = 260) #500 mm (2.50) 0.41 (Fisher).500 mm (1.15) CD4 cell count nadir (n = 250) #200 mm (2.36) 0.66 (Fisher).200 mm (1.11) Current viral load (n = 246) $1000 copies/ml (1.18) 0.67 (Fisher),1000 copies/ml (2.04) Efavirenz as part of HAART (n = 155) Yes (1.72) 0.13 (Fisher) MSM, men who have sex with men; IVDU, intravenous drug users q 2009 Lippincott Williams & Wilkins
4 J Acquir Immune Defic Syndr Volume 52, Number 4, December 1, 2009 Neurocognitive Performance in HIV Infection FIGURE 1. Scattergram showing the distribution of IHDS scores by age in both groups. testing performance. The presence of coexisting diseases, particularly neurodegenerative disorders among older patients limits our ability to identify HIV-specific etiologies. HIV infection could increase the risk for other age-related neurodegenerative disorders. 20 Historically, there was little need to consider age-related neurodegenerative diseases as a contributing factor to neurocognitive impairment in HIV infection because the young age of HIV-infected population. Today, prolonged life expectancy, arise the issue of aging as a relevant factor in neurocognitive impairment. HIV infection could lower the threshold for the clinical presentation of other neurodegenerative diseases. Early diagnosis of HIV neurocognitive impairment is crucial, particularly, because it is a potentially treatable condition with antiretroviral therapy. The benefit of HAART on neuropsychological function in patients with advanced diseases is well known; neurocognitive improvement has been associated with a decline in cerebrospinal fluid HIV-1 RNA in patients who started HAART therapy after diagnosis of a cognitive deficit. 21,22 IHDS proved to be an easy to perform tool in a Spanish-speaking population from a developing country. Besides, it proved not to be time consuming and could be provided by nonneurologists. Within different regions, different subtypes (clades) of HIV-1 predominate, each with possible variations in disease progression and incidence of HAD. There has been some suggestions that the neurotoxicity of clade C is less than that of other clades. 23 So far, most studies about incidence and prevalence of HAD have been conducted in the developed world and in North America, in particular, where clade B predominates. In Argentina, clades B and BF are the predominant clades. Our study has several limitations. First, the population we studied has a preserved immune status and therefore the risk of HIV-associated dementia could be low. Second, IHDS has been developed to screen for HIV-associated dementia and probably is not sensitive enough to screen for HIV-1 associated minor cognitive disorders such as ANI or HIVassociated minor neurocognitive disorder. However, the most relevant limitation of IHDS has been shown to be specificity, not sensitivity. 10 The IHDS cannot be used to distinguish between different stages of HIV dementia, although progressively lower mean IHDS scores did correspond to greater dementia severity in a previous study. 10 Third, this was a crosssectional analysis, and the sample size was not big enough to be powered to show differences according to some of the analyzed variables such as risk factor for HIV infection. Fourth, our population was mainly composed by men who have sex with men and highly educated patients; education is known to be a protecting factor for neurocognitive impairment. 24 Finally, patients on HAART received drugs with different central nervous system penetration. According to our results, patients with preserved immune status do not seem to be at high risk of developing clinically significant neurocognite impairment measured by IHDS, and it does not seem to have any difference between those being on antiretroviral therapy with controlled plasma viral load and those who are not on antiretroviral therapy. Only older patients could be at higher risk. ACKNOWLEDGMENT The authors would like to thank Dr. Karl Goodkin for his substantial contribution to this paper. REFERENCES 1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69: Hinkin CH, Castellon SA, Atkinson JH, et al. Neuropsychiatric aspects of HIV infection among older adults. J Clin Epidemiol. 2001;54(Suppl 1): S44 S Chiesi A, Vella S, Dally LG, et al. Epidemiology of AID S dementia complex in Europe. J Acquir Immune Defic Syndr. 1996;11: McArthur JC, Cohen BA, Selnes OA, et al. Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV-1 infected individuals: results from the Multicenter AIDS Cohort Study. Ann Neurol. 1989;26: Sacktor NC, Bacellar H, Hoover DR, et al. Psychomotor slowing in HIV infection. A predictor of dementia, AIDS and death. Neurovirol. 1996;2: Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIVinfected adults: affect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19 S25. q 2009 Lippincott Williams & Wilkins 525
5 Lopardo et al J Acquir Immune Defic Syndr Volume 52, Number 4, December 1, Giancola ML, Lorenzini P, Balestra P, et al. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIVinfected patientes responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;41: Folstein MF, Folstein SE, McHugh PR. Mini-Mental State : a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12: McArthur JC. Neurologic manifestations of AIDS. Medicine (Baltimore). 1987;66: Sacktor NC, Wong M, Nakasujja N, et al. The international dementia scale: a new rapid screening test for HIV dementia. AIDS. 2005;19: Berger JR, Brew B. An international screening tool for HIV dementia. AIDS. 2005;19: Davis HF, Skolasky RL Jr, Selnes OA, et al. Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read. 2002;12:29 31, MacArthur JC, Cohen BA, Selnes OA, et al. Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV-1 infected individuals: results from the Multicenter AIDS Cohort Study. Ann Neurol. 1989;26: Miller EN, Selnes OA, MacArthur JC, et al. Neuropsychological performance in HIV-1 infected homosexual men: The Multicenter AIDS Cohortt Study (MACS). Neurology. 1990;40: Department of Health and Human Services. Panel on Clinical Practices for Treatment of HIV infection convened by the US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents Available at: Accessed December 7, Sacktor NC. The epidemiology of human immunodeficiency virusassociated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002;8(Suppl 2): Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, Neurology. 2001;56: Gazzard BG. Efavirenz in the management of HIV infection. Int J Clin Pract. 1999;53: Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 Cohort. Neurology. 2004;63: Valcour V, Paul R. HIV infection and dementia in older adults. Clin Infect Dis. 2006;42: Marra CM, Lockhart D, Zunt JR, et al. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology. 2003;60: Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004;36: Joska JA, Fincham DS, Stein DJ, et al. Clinical correlates of HIVassociated neurocognitive disorders in South Africa. AIDS Behav. Mar 27, E-pub ahead of print. 24. De Ronchi D, Faranca I, Berardi D, et al. Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors. Arch Neurol. 2002;59: q 2009 Lippincott Williams & Wilkins
COGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL
COGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL Principal Investigator Dr. Zaheer Bagha Supervisors Prof. E. Amayo Prof. A. M. Adam Dr. J. O. Mecha INTRODUCTION
More informationImprovement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors
(2000) 6, 84 ± 88 ã 2000, Inc. www.jneurovirol.com Short Communication Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors Ned Charlton Sacktor*,1, Richard
More informationApproach to HIV Associated Neurocognitive disorders (HAND)
Approach to HIV Associated Neurocognitive disorders (HAND) Dinesh Singh MB ChB (Natal), M Med (Psych) (Natal), F CPsych (SA), MS (epi) (Columbia, USA), PhD (candidate UKZN) 2 October 2009 ICC, Durban Overview
More informationThe prevalence of HIV-associated neurocognitive
The authors investigated the combined age and HIV effects on cognitive functions in 146 individuals, 116 of whom had HIV infection. Fortytwo percent had HIV-associated neurocognitive disorder, and all
More informationInternational Symposium on. Barcelona, May 5 th and 6 th 2011
th International Symposium on Barcelona, May 5 th and 6 th 2011 4rd Symposium on Psychiatry and HIV --- Barcelona, May 6th 2010 Neurocognitive Testing in HIV Infection: How to Implement this Assessment
More informationThe Relationship Between Age and Cognitive Function in HIV-Infected Men
The Relationship Between Age and Cognitive Function in HIV-Infected en Emily C. Kissel Nicole D. Pukay-artin, B.A. Robert A. Bornstein, Ph.D. Several studies have identified increased age as a risk factor
More informationHIV Dementia Scale and Psychomotor Slowing The Best Methods in Screening for Neuro-AIDS
HIV Dementia Scale and Psychomotor Slowing The Best Methods in Screening for Neuro-AIDS Hans-Jürgen von Giesen, M.D. Bernhard A. Haslinger, M.D. Simone Rohe Hubertus Köller, M.D. Gabriele Arendt, M.D.
More informationWhile great progress has been made in understanding
Human immunodeficiency virus (HIV) DNA in peripheral blood mononuclear cells was previously associated with neuropsychological function. By including individuals encompassing the full range of HIV-1-associated
More informationHow to Implement this Assessment in the Clinical Prac5ce?
5th Interna*onal Symposium on Neuropsychiatry HIV - - - Barcelona, May 24-25th, 2012 Neuropsychological Screening in HIV Infec6on: How to Implement this Assessment in the Clinical Prac5ce? Jose A. Muñoz-
More informationHIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project
DOI: 10.1111/hiv.12137 ORIGINAL RESEARCH HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project NS Ku, 1 Y Lee, 2 JY Ahn, 1 JE Song, 1 MH Kim, 1 SB Kim, 1 SJ Jeong,
More informationDr Ria Daly. Birmingham Heartlands Hospital. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Ria Daly Birmingham Heartlands Hospital 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual Conference of the
More informationORIGINAL CONTRIBUTION. Factors Associated With Incident Human Immunodeficiency Virus Dementia
ORIGINAL CONTRIBUTION Factors Associated With Incident Human Immunodeficiency Virus Dementia Yaakov Stern, PhD; Michael P. McDermott, PhD; Steven Albert, PhD; Donna Palumbo, PhD; Ola A. Selnes, PhD; Justin
More informationDifferential diagnosis between depression and neurocognitive impairment in HIV-infected persons
Differential diagnosis between depression and neurocognitive impairment in HIV-infected persons Dr. Adriana Carvalhal, MD, MSc, PhD University of Toronto - Canada Disclosure Research: Canadian Institute
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More information3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract #
3rd IAS Conference on HIV Pathogenesis and Treatment 24 27 July 2005, Rio de Janeiro, Brazil Poster Number Abstract # TuFo0106 TuFo0106 Characterization of Anemia in HIV-infected (HIV+) Subjects Treated
More informationHIV-Associated Neurocognitive Disorders (HAND) Aroonsiri Sangarlangkarn, MD, MPH, Jonathan S. Appelbaum, MD, FACP
HIV-Associated Neurocognitive Disorders (HAND) Aroonsiri Sangarlangkarn, MD, MPH, Jonathan S. Appelbaum, MD, FACP Educational Objectives By the end of the session, learners will be able to: 1. Describe
More informationDepression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention
The Alfred Hospital Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Final Report August 2005 Chief Investigator Associate Professor Anne Mijch Infectious Diseases
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationThe Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV
The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV Arianna Perra, P syd, Moira Dux, PhD Terry Lee- Wilk, PhD HIV and HCV in the VA VA is the largest provider
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION An Evaluation of Neurocognitive Status and Markers of Immune Activation as Predictors of Time to Death in Advanced HIV Infection Jeffrey J. Sevigny, MD; Steven M. Albert, PhD; Michael
More informationProgress in understanding the pathogenesis of HIV-1-
The authors previously found a strong association between elevated HIV proviral DNA (HIV DNA) and a diagnosis of HIV-1-associated dementia (HAD) vs. normal cognition. It is unclear whether HIV DNA globally
More informationCognitive impairment among Indonesia HIV naïve patients
Neurology Asia 2015; 20(2) : 155 160 Cognitive impairment among Indonesia HIV naïve patients 1 Riwanti Estiasari MD, 1 Darma Imran MD, 1 Diatri Nari Lastri MD, 1 Pukovisa Prawirohardjo MD, 1,2 Patricia
More informationSustained cognitive decline in HIV infection: relationship to CD4+ cell count, plasma viremia and p24 antigenemia
Short Communication Journal of NeuroVirology (1998) 4, 95 ± 99 ã 1998 Journal of NeuroVirology, Inc. http://www.jneurovirol.com : relationship to CD4+ cell count, plasma viremia and p24 antigenemia Gerald
More informationInternational HIV Dementia Scale:
ORIGINAL RESEARCH International HIV Dementia Scale: screening for HIV-associated neurocognitive disorders in occupational settings CH Van Wijk 1,2 and WAJ Meintjes 2 1 Institute for Maritime Medicine,
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationThe availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings
Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIVinfected Asian children stable on first-line NNRTI-based cart T Sudjaritruk, DC Boettiger, NV Lam, KAM
More informationThe prevalence and incidence of neurocognitive impairment in the HAART era
The prevalence and incidence of neurocognitive impairment in the HAART era Kevin R. Robertson a, Marlene Smurzynski b, Thomas D. Parsons a, Kunling Wu b, Ronald J. Bosch b, Julia Wu b, Justin C. McArthur
More informationDefinitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders
Definitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders Prepared by Igor Grant for Working Group 1 consisting of: Desiree Byrd, Mariana Cherner, David
More informationChanges in viral suppression status among US HIV-infected patients receiving care
CONCISE COMMUNICATION Changes in viral suppression status among US HIV-infected patients receiving care Nicole Crepaz a, Tian Tang b, Gary Marks a and H. Irene Hall a Objective: To examine changes in viral
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationHigh rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents
High rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents YasotharanParamesparan, Jane Ashby, Lucy Garvey, Caroline Foster, Sarah Fidler, Alan Winston Background
More informationForget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?)
Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?) Dr Simon Rackstraw FRCP Medical Director, Mildmay Hospital, London Consultant
More informationHIV Neurology Persistence of Cognitive Impairment Despite cart
HIV Neurology Persistence of Cognitive Impairment Despite cart Victor Valcour MD PhD Professor of Medicine Memory and Aging Center, Dept. of Neurology University of California San Francisco, USA 8 th International
More informationHIV-1 Dual Infection and Neurocognitive Impairment
HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral
More informationPART IV! CLINICAL IMPLICATIONS
PART IV! CLINICAL IMPLICATIONS Background Biological link between HIV and aging paints a grim picture, however The benefits of ART strongly outweigh the risks associated with ongoing immune activation
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationDynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy
Published Ahead of Print on May 27, 2009 as 10.1212/WNL.0b013e3181ab2b3b Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy L.A. Cysique, PhD F. Vaida, PhD
More informationPrevalence and factors associated with probable HIV dementia in an African population: A cross-sectional study of an HIV/AIDS clinic population
Nakku et al. BMC Psychiatry 2013, 13:126 RESEARCH ARTICLE Open Access Prevalence and factors associated with probable HIV dementia in an African population: A cross-sectional study of an HIV/AIDS clinic
More informationOriginal Article. J Young Pharm, 2016; 8(3): A multifaceted peer reviewed journal in the field of Pharmacy
J Young Pharm, 2016; 8(3): 279-283 A multifaceted peer reviewed journal in the field of Pharmacy www.jyoungpharm.org www.phcog.net Original Article Impact of HIV associated neurocognitive disorders on
More informationSystemic monocyte activation levels and developmental milestone attainment in HIV-infected. infants initiating antiretroviral therapy.
Systemic monocyte activation levels and developmental milestone attainment in HIV-infected infants initiating antiretroviral therapy Ira Martopullo A thesis submitted in partial fulfillment of the requirements
More informationTable S1. Number of eligible individuals by cohort, HIV-CAUSAL and CNICS Collaborations,
Cohort Table S1. Number of eligible individuals by cohort, HIV-CAUSAL and CNICS Collaborations, 2000-2013 No. of antiretroviraltherapy naïve individuals No. initiated cart regimen in 2000 or later No.
More informationLambros Messinis PhD. Neuropsychology Section, Department of Neurology, University of Patras Medical School
Lambros Messinis PhD Neuropsychology Section, Department of Neurology, University of Patras Medical School Type 2 Diabetes Mellitus is a modern day epidemic Age is a significant predictor of diabetes Males
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationEffect of ageing on neurocognitive function by stage of HIV infection: evidence from the Multicenter AIDS Cohort Study
Effect of ageing on neurocognitive function by stage of HIV infection: evidence from the Multicenter AIDS Cohort Study Karl Goodkin, Eric N Miller, Christopher Cox, Sandra Reynolds, James T Becker, Eileen
More informationHIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS
HIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS WITH LOW CD4 COUNTS IN 2008 AND FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS FROM 2004 THROUGH 2008 For the Boston
More informationThe Role of Cardiovascular Risk and Aging in Memory Performance in a Sample of Veterans with HIV
The Role of Cardiovascular Risk and Aging in Memory Performance in a Sample of Veterans with HIV LYNN KAKOS, PH.D. VA MARYLAND HEALTH CARE SYSTEM (VAMHCS) OBJECTIVES HIV in the VA Neurocognitive profile
More informationHIV/AIDS MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN HIV/AIDS MEASURES GROUP: #159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed #160. HIV/AIDS: Pneumocystis
More informationAntiviral Therapy 2016; 21: (doi: /IMP3052)
Antiviral Therapy 2016; 21:725 730 (doi: 10.3851/IMP3052) Short communication HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health
More informationIncidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART)
376 Neurology, University Clinic Essen, Hufelandstrasse 55, 45122 Essen, Germany M Maschke O Kastrup A Hufnagel Dermatology S Esser U Hengge Internal Medicine B Ross Correspondence to: Dr Matthias Maschke
More informationCOGNITIVE FUNCTIONING IN ADULTS AGING WITH HIV: EXPLORING COGNITIVE SUBTYPES AND INFLUENTIAL FACTORS PARIYA L. FAZELI
COGNITIVE FUNCTIONING IN ADULTS AGING WITH HIV: EXPLORING COGNITIVE SUBTYPES AND INFLUENTIAL FACTORS by PARIYA L. FAZELI DAVID E. VANCE, COMMITTEE CO-CHAIR KARLENE K. BALL, COMMITTEE CO-CHAIR VIRGINIA
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationAntiviral Therapy 2015; 20: (doi: /IMP2926)
Antiviral Therapy 2015; 20:441 447 (doi: 10.3851/IMP2926) Original article Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for
More informationORIGINAL CONTRIBUTION. Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion
ORIGINAL CONTRIBUTION Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion Thomas D. Marcotte, PhD; Reena Deutsch, PhD; J. Allen McCutchan, MD;
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationNeuropsychological assessment in HIV/AIDS and its challenges in Galati County
Neuropsychological assessment in HIV/AIDS and its challenges in Galati County Manuela Arbune Dunarea de Jos U i e sit Galati București, October 5-6, 2015 Background HAND persists despite ARV (~50%). Neu
More informationnatural history of the disease, there is no rationale for limiting screening of cognitive
Assessment, Diagnosis and Treatment of Human Immunodeficiency Virus (HIV)- associated Neurocognitive Disorders (HAND): AConsensus Report of the Mind Exchange Program Supplementary Materials Full practical
More information227 28, 2010 MIDTERM EXAMINATION KEY
Epidemiology 227 April 28, 2010 MIDTERM EXAMINATION KEY Select the best answer for the multiple choice questions. There are 64 questions and 9 pages on the examination. Each question will count one point.
More informationAntiviral Therapy 14:
Antiviral Therapy 14:451 457 Short communication CD4 + T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4 + T-cell counts >200 cells/mm
More informationNeurocognitive impairment still occurs in HIV-infected individuals even in those treated with highly active
REVIEWS IMAJ VOL 17 JANUARY 2015 HIV-Associated Neurocognitive Disorders (HAND) Daniel Elbirt MD 1, Keren Mahlab-Guri MD 1, Shira Bezalel-Rosenberg MD 1, Harpreet Gill BHSc 2, Malka Attali MD 1 and Ilan
More informationDOI: /hiv British HIV Association HIV Medicine (2013), 14, SHORT COMMUNICATION
DOI: 10.1111/hiv.12008 SHORT COMMUNICATION Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationMalaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh
Malaysian Consensus Guidelines on Antiretroviral Therapy 2017 Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh Acknowledgement Table of contents Evolution of when to initiate therapy ART improves survival
More informationSupplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.
Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,
More informationNeurologic disorders incidence in HIV+ vs HIV men : Multicenter AIDS Cohort Study,
Neurologic disorders incidence in HIV+ vs HIV men : Multicenter AIDS Cohort Study, 1996 2011 Farrah J. Mateen, Russell T. Shinohara, Marco Carone, et al. Neurology; Published online before print October
More informationA Comparison of Clinical Features among Patients Suffering from Depression in HIV Positive and HIV Negative Cases
Original Article A Comparison of Clinical Features among Patients Suffering from Depression in HIV Positive and HIV Negative Cases Rajdeep Kaur, Ramandeep Kaur Civil Hospital, Gurdaspur, Punjab Abstract
More informationCan high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?
Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? Matteo Vassallo a,b, Jacques Durant a, Virginie Biscay a, Christine
More informationHIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital
HIV AND LUNG HEALTH Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital Introduction HIV infection exerts multiple effects on pulmonary immune responses: Generalised state of immune
More informationContemporary Issues in Adolescent Care. Mental Health
Contemporary Issues in Adolescent Care Mental Health Outline of presentation Normal adolescent development Impact of HIV on adolescents Mental Disorders in adolescents Mental disorders in adolescents with
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationChin-Hui Yang, M.D. Hui-Rong Liu, Sung-Yin Chen, Yen-Fang Huang, Shih-Yan Yang Third Division, Centers for Disease Control, Department of Health,
Comparison of ff Factors affecting the mortality rate of Injecting Drug Users with HIV infection in Taiwan Chin-Hui Yang, M.D. Hui-Rong Liu, Sung-Yin Chen, Yen-Fang Huang, Shih-Yan Yang Third Division,
More informationHIV-associated cognitive disorders: Scientific discoveries through international collaborations in Thailand Valcour, Victor
UvA-DARE (Digital Academic Repository) HIV-associated cognitive disorders: Scientific discoveries through international collaborations in Thailand Valcour, Victor Link to publication Citation for published
More informationAntiviral Therapy 2013; 18: (doi: /IMP2560)
Antiviral Therapy 2013; 18:153 160 (doi: 10.3851/IMP2560) Original article Revised central nervous system neuropenetrationeffectiveness score is associated with cognitive disorders in HIV-infected patients
More informationMetabolic Syndrome is Associated with Neurocognitive Deficits in Persons Living with HIV
Metabolic Syndrome is Associated with Neurocognitive Deficits in Persons Living with HIV Jessica L. Montoya, Ph.D. Postdoctoral Fellow Department of Psychiatry, UC San Diego 9 th International Workshop
More informationHIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital
HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per
More informationTitle: Analysis of the immunologic status of a newly diagnosed HIV positive population in China
Author's response to reviews Title: Analysis of the immunologic status of a newly diagnosed HIV positive population in China Authors: Yinzhong Shen (027465@163.com) Hongzhou Lu (luhongzhou@fudan.edu.cn)
More informationClinical Epidemiology of Frailty in HIV Infection. Joseph B. Margolick, MD, PhD Johns Hopkins Bloomberg School of Public Health
Clinical Epidemiology of Frailty in HIV Infection Joseph B. Margolick, MD, PhD Johns Hopkins Bloomberg School of Public Health HIV and Aging 4 Similarities between HIV and aging at the biological level
More informationComparing adherence items of missed doses with different timeframes and their associations with viral load in routine clinical care
Comparing adherence items of missed doses with different timeframes and their associations with viral load in routine clinical care R Nance, JAC Delaney, R Fredericksen, A Church, A Harrington, P Crane,
More informationEngagement is Key to Effectiveness of Individualized Texting for Adherence Building (itab) Among HIV+ Methamphetamine Users
Engagement is Key to Effectiveness of Individualized Texting for Adherence Building (itab) Among HIV+ Methamphetamine Users J.L. Montoya, A.S. Rooney, B. Gouaux, A. Umlauf, C. Sanders, C.A. Depp, J.H.
More informationHIV and Brain Func.on. Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital
HIV and Brain Func.on Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital HIV and the Brain When can HIV affect the brain? Seroconversion Long term infected (not
More informationPredictors of Adherence to Antiretroviral Medications in Children and Adolescents With HIV Infection
ARTICLE Predictors of Adherence to Antiretroviral Medications in Children and Adolescents With HIV Infection Paige L. Williams, PhD a, Deborah Storm, PhD, RN b, Grace Montepiedra, PhD a, Sharon Nichols,
More information11/7/2012. HIV disease: Chronic Disease Patients are aging with their HIV disease on effective antiretroviral therapy (ART)
The Journey of HIV Infected Infected Patients Over 50: Implications for Nursing Care Objectives Julie Gumowski, RN, BSN Margaret Caplan, M.D. November 17, 2012 SAIC Frederick To discuss the prevalence
More informationMichael Healy August 8, 2012 Irving CRC Research Proposal. 1. Study Purpose and Rationale
Michael Healy August 8, 2012 Irving CRC Research Proposal Prevalence of diarrhea and gastrointestinal infection in severely malnourished Human Immunodeficiency Virus (HIV) infected children in Durban,
More informationClinical notes: Management of HAART in patients with HAND
Clinical notes: Management of HAART in patients with HAND Paola Cinque Dipartment of Infectious Diseases San Raffaele Scientific Institute, Milano, Italy 11 Residential Course on Clinical Pharmacology
More informationLow prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons
Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons Nancy F. Crum-Cianflone, David J. Moore, Scott Letendre, et al. Neurology 2013;80;371; Published online before
More informationCAB 59: HIV and neurocogni5ve impairment
HIV Neurology CAB 59: HIV and neurocogni5ve impairment Friday 8 th July 2016 Dr Nick Davies Consultant Neurologist, Chelsea & Westminster Hospital & Imperial College NHS Trust (Charing Cross Hospital),
More informationHAND is Common and Important in Patients on ART
HAND is Common and Important in Patients on ART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego How is HAND diagnosed? How prevalent is it? Points
More informationDefinitions of antiretroviral treatment failure for measuring quality outcomes
DOI: 10.1111/j.1468-1293.2009.00808.x r 2010 British HIV Association HIV Medicine (2010), 11, 427 431 ORIGINAL RESEARCH Definitions of antiretroviral treatment failure for measuring quality outcomes A
More informationCHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
More informationImaging in Pediatric `neurohiv Dr Jackie Hoare Head of Liaison Psychiatry Groote Schuur Hospital, UCT
Imaging in Pediatric `neurohiv Dr Jackie Hoare Head of Liaison Psychiatry Groote Schuur Hospital, UCT ? Spectrum of Neurocognitive disorders The adult literature on HIV related CNS damage supports a spectrum
More informationResilience in Women with HIV: Relationships with Abuse History, Medication Adherence and HIV Viral Load
Resilience in Women with HIV: Relationships with Abuse History, Medication Adherence and HIV Viral Load Sannisha K. Dale 1, Mardge H. Cohen 2, Kathleen M. Weber 3, Gwendolyn Kelso 1, Ruth C. Cruise 1,
More informationEPIDEMIOLOGY AND PREVENTION
EPIDEMIOLOGY AND PREVENTION Age, Race/Ethnicity, and Behavioral Risk Factors Associated With Per Contact Risk of HIV Infection Among Men Who Have Sex With Men in the United States Hyman M. Scott, MD, MPH,*
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationDate of study period: April 12 May 7, 2010 and August September, 2010
Classification of antiretroviral therapy failure using immunologic and clinical versus virologic monitoring in HIV-infected children and adolescents in Cambodia Date of study period: April 12 May 7, 2010
More informationTechnical appendix to How should access to antiretroviral treatment be measured? Published in the Bulletin of the World Health Organization
Technical appendix to How should access to antiretroviral treatment be measured? Published in the Bulletin of the World Health Organization Leigh F. Johnson Andrew Boulle Centre for Infectious Disease
More informationA semantic verbal fluency test for English- and Spanish-speaking older Mexican-Americans
Archives of Clinical Neuropsychology 20 (2005) 199 208 A semantic verbal fluency test for English- and Spanish-speaking older Mexican-Americans Hector M. González a,, Dan Mungas b, Mary N. Haan a a University
More informationOpportunistic infections in the era of cart, still a problem in resource-limited settings
Opportunistic infections in the era of cart, still a problem in resource-limited settings Cristiana Oprea Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania Assessment
More informationInternational Forum on HIV and Rehabilitation Research
Neurocognitive screening and behavioural interventions for HIV-Associated Neurocognitive Disorders (HAND) International Forum on HIV and Rehabilitation Research Translating Research Evidence from the Canada-UK
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More information